Please login to the form below

Not currently logged in
Email:
Password:

Sir Tom Blundell to remain as chair of UK’s biotech research council

Reappointed to government role to support research

BBSRC Sir Tom BlundellSir Tom Blundell has been reappointed as chair of the UK's Biotechnology and Biological Sciences Research Council (BBSRC), a government-funded organisation to support research in the UK.

This is Sir Tom's second term in the position, having originally been appointed to the role in July 2009. He will now serve a further two years more than his original four-year term, with his reappointment lasting until June 30, 2015.

He was also one of the initial founders of the BBSRC in 1994, serving for two years as its chief executive.

“I am delighted that Sir Tom Blundell has agreed to remain as chair of BBSRC,” said David Willetts, minister for universities and science.

“His extensive academic experience in the field of biochemistry coupled with his active role in science policy makes him an invaluable asset to the council.”

This experience includes Sir Tom's current role as professor emeritus and director of research in biochemistry at the University of Cambridge. 

He was previously head of the School of Biological Sciences in Cambridge and Sir William Dunn Professor of Biochemistry.

Sir Tom has prior experience in science policy, serving as a member of the advisory group to the Prime Minister in the 1980s.

He has also spent time as chairman of the Royal Commission on Environmental Pollution, president of the UK Biosciences Federation and president of UK Science Council.

In addition to his academic and policy background, Sir Tom has industry experience, serving as non-executive director of biotech Celltech from 1996 to 2005 and holding advisory roles with Pfizer, UCB and SmithKline Beecham (now part of GSK).

27th February 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics